Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iPSC-NK Cells Targeting CLL1 or CD33 in r/r AML
NCT06367673Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Apr 2024
- Primary completion
- Mar 2026
- Modality
- Patient-derived iPSCs, Lymphokine-Activated Killer Cells, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OE226-iNK cells in acute myeloid leukemia (AML), sponsored by Zhejiang University. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 28 days. Started Apr 2024; status: recruiting.
02
Drugs
OE226-iNK cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06367673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06367673.